WO2004019880A3 - Proteines interagissant avec aw755252 et leur utilisation - Google Patents

Proteines interagissant avec aw755252 et leur utilisation Download PDF

Info

Publication number
WO2004019880A3
WO2004019880A3 PCT/US2003/026997 US0326997W WO2004019880A3 WO 2004019880 A3 WO2004019880 A3 WO 2004019880A3 US 0326997 W US0326997 W US 0326997W WO 2004019880 A3 WO2004019880 A3 WO 2004019880A3
Authority
WO
WIPO (PCT)
Prior art keywords
protein complexes
interacting proteins
disorders
diseases
group1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2003/026997
Other languages
English (en)
Other versions
WO2004019880A2 (fr
Inventor
Chuck Hensel
Takeshi Sakamoto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TADEKA CHEMICAL INDUSTRIES Ltd
TADEKA CHEMICAL IND Ltd
Original Assignee
TADEKA CHEMICAL INDUSTRIES Ltd
TADEKA CHEMICAL IND Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TADEKA CHEMICAL INDUSTRIES Ltd, TADEKA CHEMICAL IND Ltd filed Critical TADEKA CHEMICAL INDUSTRIES Ltd
Priority to AU2003265814A priority Critical patent/AU2003265814A1/en
Publication of WO2004019880A2 publication Critical patent/WO2004019880A2/fr
Anticipated expiration legal-status Critical
Publication of WO2004019880A3 publication Critical patent/WO2004019880A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne des complexes protéiques comprenant AW755252 et une ou plusieurs protéines choisies dans le groupe constitué par GROUP1. L'invention concerne également des méthodes d'utilisation de ces complexes protéiques dans le diagnostic de maladies et de troubles. En outre, lesdits complexes protéiques sont également utiles dans des analyses de criblage destinées à identifier des composés permettant de traiter et/ou prévenir efficacement des maladies et des troubles associés à AW755252 et ses interacteurs.
PCT/US2003/026997 2002-08-28 2003-08-26 Proteines interagissant avec aw755252 et leur utilisation Ceased WO2004019880A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003265814A AU2003265814A1 (en) 2002-08-28 2003-08-26 Aw755252-interacting proteins and use thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US40661302P 2002-08-28 2002-08-28
US60/406,613 2002-08-28
US41165702P 2002-09-18 2002-09-18
US60/411,657 2002-09-18

Publications (2)

Publication Number Publication Date
WO2004019880A2 WO2004019880A2 (fr) 2004-03-11
WO2004019880A3 true WO2004019880A3 (fr) 2006-06-29

Family

ID=31981419

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/026997 Ceased WO2004019880A2 (fr) 2002-08-28 2003-08-26 Proteines interagissant avec aw755252 et leur utilisation

Country Status (2)

Country Link
AU (1) AU2003265814A1 (fr)
WO (1) WO2004019880A2 (fr)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001092567A2 (fr) * 2000-05-30 2001-12-06 Medigene Ag Nouveau genes cibles pour les maladies du coeur

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001092567A2 (fr) * 2000-05-30 2001-12-06 Medigene Ag Nouveau genes cibles pour les maladies du coeur

Also Published As

Publication number Publication date
WO2004019880A2 (fr) 2004-03-11
AU2003265814A1 (en) 2004-03-19
AU2003265814A8 (en) 2004-03-19

Similar Documents

Publication Publication Date Title
AU2002366641A1 (en) Methods for inhibiting ocular processes
WO2004007743A3 (fr) Utilisation d'acides nucleiques cpg dans les maladies a prions
IN2014DN05011A (fr)
WO2004011611A3 (fr) Anticorps anti-taci et utilisations de ceux-ci
WO2004074455A3 (fr) Variants de la region fc
WO2003011115A3 (fr) Agents de contraste multimères ciblés à base de peptides
WO2003066661A3 (fr) Anticorps humains du dr4 et utilisations
EP2154157A3 (fr) variants de la region Fc
WO2006038208A3 (fr) Agents capable de reguler a la baisse un hif-1$g(a) dependant de msf-a et utilisation de ceux-ci pour traiter un cancer
WO2004035742A3 (fr) Ensembles d'anticorps numeriques diriges contre des epitopes courts et leurs methodes d'utilisation
WO1999020747A3 (fr) NOUVELLE KINASE HUMAINE POINT DE CONTROLE, hCDS1, COMPOSITIONS ET METHODES ASSOCIEES
WO2004099388A3 (fr) Complexes de polypeptides cbl-b et methodes associees
WO2003087138A3 (fr) Procedes d'identification de facteurs polypeptidiques ayant une interaction avec l'arn
WO2004083241A3 (fr) Proteines interagissant avec btc et utilisation de ces proteines
WO2005000876A3 (fr) Proteines de la famille des proteines a doigts de zinc (ring finger) et leurs utilisations
AU2002368056A1 (en) Novel pla2 enzyme, it's antibody, enzyme inhibitor and use and the preparation methods thereof
WO2003027251A3 (fr) Nouvelles molecules de la famille des proteines du domaine de pyrine et leur utilisation
WO2002073212A3 (fr) Analyses diagnostiques destinees a la maladie d'alzheimer
WO2004047757A3 (fr) Diagnostic et traitement des cancers hematopoietiques
WO2003076472A3 (fr) Anticorps specifiques des neoplasmes et leurs utilisations
AU2003252383A1 (en) Test piece for protein assay and process for producing the same
WO2003087051A3 (fr) Procedes d'identification de sites allosteriques
EP1582589A4 (fr) Complexe de proteines, processus de fabrication et d'utilisation dudit complexe
WO2002062205A3 (fr) Methodes de diagnostic et de traitement des cardiopathies
WO2004005540A3 (fr) Utilisations de substances qui se lient a ngal pour le diagnostic et le traitement de maladies cancereuses

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP